BMP-7 (OP-1)

BMP-7 stands apart from most of this catalogue in two ways. First, it is not a peptide: the molecule is a recombinant homodimeric glycoprotein of roughly 35 kDa, its two subunits joined by an interchain disulfide and folded around the cystine knot typical of the TGF-β superfamily. A 5–30 residue synthetic peptide and a recombinant protein of this size differ in manufacture, stability and solution behaviour. Second, BMP-7 is one of the few compounds in this category that actually reached clinical use and then left it — for reasons only partly related to efficacy.

Signalling logic: one superfamily, two opposing branches

TGF-β1 and BMP-7 belong to the same superfamily but engage different receptor complexes and different R-Smads. TGF-β1 signals through ALK5 to phosphorylate Smad2/3, the profibrotic branch. BMP-7 signals through type I receptors (ALK2/ALK3/ALK6) to phosphorylate Smad1/5/8. Both branches compete for the shared co-mediator Smad4, so in kidney injury models raising BMP-7 signalling shifts the balance against the TGF-β1-driven fibrotic programme. It is this counter-regulatory mechanism, rather than a simple growth-factor effect, that made BMP-7 an antifibrotic research subject.

Two independent research lines

Orthopaedic. As OP-1 on a collagen carrier, the protein received in the US not full approval but a Humanitarian Device Exemption — a restricted pathway for tibial nonunion and revision posterolateral fusion. The commercial story ended before the scientific one: assets moved from Stryker Biotech to Olympus Biotech in 2010, and manufacturing was halted in 2014.

Renal. BMP-7 is most highly expressed in the adult kidney, and its knockout in mice produces severe renal dysplasia. Preclinical work from 1998–2004 showed attenuated injury in ischaemia models and antagonism of TGF-β1-induced epithelial-to-mesenchymal transition. No clinical trial of BMP-7 in human kidney disease has been conducted. This branch has remained entirely preclinical for over twenty years.

Why the direction stalled

The principal obstacle is pharmacokinetic: soluble recombinant BMPs are cleared from circulation within minutes, so a systemic antifibrotic cannot be built from the naked protein. Orthopaedic use sidestepped this by local implantation on a carrier — a fundamentally different pharmacology from the systemic hypothesis. Attempts to overcome the limitation (albumin fusion, micellar constructs, BMP-signal enhancers) remain experimental.

A full treatment of mechanism, evidence and limitations is in the BMP-7 reference monograph. Related items sit under Tissue Repair and Anti-fibrosis.

Status: item in preparation, not in stock. The notification form on this page collects requests to be alerted on availability.